D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 25 2025
0mins
Source: Benzinga
Top Performing Mid-Cap Stocks: D-Wave Quantum Inc. saw a 53.47% increase after launching its Advantage2 quantum system, while Regencell Bioscience Holdings and Advance Auto Parts also experienced significant gains of 42.49% and 38.94%, respectively, following positive company announcements.
Other Notable Stock Increases: Merus N.V. rose by 32.68% due to promising clinical trial data, Oklo Inc. gained 29.56% amid regulatory easing reports, and several other mid-cap stocks like Sibanye-Stillwater Limited and BGM Group Ltd. also showed strong performance last week.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will be ineligible for compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to seek compensation through litigation.
- Legal Risk Disclosure: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and regulatory scrutiny, which could lead to significant financial losses, highlighting the urgent need for corporate transparency and compliance.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovered hundreds of millions for investors, demonstrating its expertise and resource advantages in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Regencell Bioscience Lawsuit: During the period from October 2024 to October 2025, Regencell is accused of failing to disclose market manipulation risks, exposing investors to significant financial risks, which could lead to regulatory scrutiny and impact the company's reputation and operations.
- SES AI Business Prospects Controversy: SES AI is alleged to have overstated its business prospects from January 2025 to March 2026, with logistics constraints affecting Q4 2025 revenues, raising doubts about its growth prospects for 2026 and potentially undermining investor confidence.
- FS KKR Capital Restructuring Issues: FS KKR is accused of exaggerating the effectiveness of its portfolio restructuring efforts from May 2024 to February 2026, which may lead investors to misunderstand the company's financial health and affect its market performance.
- Graphic Packaging Operational Challenges: From February 2025 to February 2026, Graphic Packaging is alleged to have failed to disclose significant inventory management issues and reduced demand, resulting in unreliable financial guidance that could negatively impact the company's future performance.
See More
Regencell Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting concerns over potential legal risks and financial losses for investors.
- Allegations of False Statements: The complaint alleges that Regencell made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks and indicated serious deficiencies in corporate governance and compliance policies.
- Risk of Legal Consequences: The heightened scrutiny from regulatory and governmental bodies could lead to substantial legal, financial, and reputational harm for investors, further exacerbating market distrust in Regencell and negatively impacting its stock performance.
- Investor Rights Protection: Investors have until June 23, 2026, to request lead plaintiff status, with the law firm promising to charge fees only upon successful recovery, ensuring that investors' rights are protected throughout the legal process.
See More
Regencell Bioscience Faces Class Action Lawsuit
- Legal Investigation Risk: On October 31, 2025, Regencell disclosed receiving a subpoena from the U.S. Department of Justice due to market volatility, indicating an investigation that may lead to fines and legal costs exceeding insurance coverage, posing significant financial risks to investors.
- Stock Price Plunge Impact: Following the investigation announcement, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, directly harming investor interests and confidence.
- False Statement Allegations: The class action lawsuit alleges that the company made materially false and misleading statements throughout the class period, failing to disclose risks of market manipulation and regulatory scrutiny, which resulted in investor losses.
- Investor Action Deadline: Investors must file a motion to be appointed as lead plaintiff in this class action lawsuit by June 23, 2026, to pursue claims under federal securities laws and protect their rights.
See More
Class Action Lawsuits Filed for Multiple Companies
- LKQ Corporation Lawsuit: A class action lawsuit for LKQ Corporation alleges that from February 27, 2023, to July 23, 2025, the company failed to disclose risks associated with losing major customers from FinishMaster, negatively impacting its operational and financial performance, with a lead plaintiff deadline of June 22, 2026.
- Regencell Bioscience Lawsuit: The class action for Regencell Bioscience Holdings Limited, covering October 28, 2024, to October 31, 2025, claims the company did not disclose vulnerabilities to market manipulation, exposing shareholders to significant financial risks, with a lead plaintiff deadline of June 23, 2026.
- Globant S.A. Lawsuit: A class action lawsuit against Globant alleges that from February 15, 2024, to August 14, 2025, the company failed to disclose decreasing demand in Latin America and wage freezes, leading to project cancellations, with a lead plaintiff deadline of June 23, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors suffering losses during these periods to contact them for legal rights information, providing phone and email contact details for inquiries.
See More
Regencell Bioscience Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, or risk losing their right to compensation.
- Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation risks and significant financial losses, highlighting the company's vulnerability to regulatory scrutiny.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, indicating its strong track record, which investors should consider when selecting legal counsel.
- Investor Rights Protection: Investors can obtain more information through Rosen Law Firm's website or by phone, and participation in the class action incurs no upfront costs, ensuring their rights to potential recoveries are protected.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will be ineligible for compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to seek compensation through litigation.
- Legal Risk Disclosure: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and regulatory scrutiny, which could lead to significant financial losses, highlighting the urgent need for corporate transparency and compliance.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovered hundreds of millions for investors, demonstrating its expertise and resource advantages in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Regencell Bioscience Lawsuit: During the period from October 2024 to October 2025, Regencell is accused of failing to disclose market manipulation risks, exposing investors to significant financial risks, which could lead to regulatory scrutiny and impact the company's reputation and operations.
- SES AI Business Prospects Controversy: SES AI is alleged to have overstated its business prospects from January 2025 to March 2026, with logistics constraints affecting Q4 2025 revenues, raising doubts about its growth prospects for 2026 and potentially undermining investor confidence.
- FS KKR Capital Restructuring Issues: FS KKR is accused of exaggerating the effectiveness of its portfolio restructuring efforts from May 2024 to February 2026, which may lead investors to misunderstand the company's financial health and affect its market performance.
- Graphic Packaging Operational Challenges: From February 2025 to February 2026, Graphic Packaging is alleged to have failed to disclose significant inventory management issues and reduced demand, resulting in unreliable financial guidance that could negatively impact the company's future performance.
See More
Regencell Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting concerns over potential legal risks and financial losses for investors.
- Allegations of False Statements: The complaint alleges that Regencell made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks and indicated serious deficiencies in corporate governance and compliance policies.
- Risk of Legal Consequences: The heightened scrutiny from regulatory and governmental bodies could lead to substantial legal, financial, and reputational harm for investors, further exacerbating market distrust in Regencell and negatively impacting its stock performance.
- Investor Rights Protection: Investors have until June 23, 2026, to request lead plaintiff status, with the law firm promising to charge fees only upon successful recovery, ensuring that investors' rights are protected throughout the legal process.
See More
Regencell Bioscience Faces Class Action Lawsuit
- Legal Investigation Risk: On October 31, 2025, Regencell disclosed receiving a subpoena from the U.S. Department of Justice due to market volatility, indicating an investigation that may lead to fines and legal costs exceeding insurance coverage, posing significant financial risks to investors.
- Stock Price Plunge Impact: Following the investigation announcement, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, directly harming investor interests and confidence.
- False Statement Allegations: The class action lawsuit alleges that the company made materially false and misleading statements throughout the class period, failing to disclose risks of market manipulation and regulatory scrutiny, which resulted in investor losses.
- Investor Action Deadline: Investors must file a motion to be appointed as lead plaintiff in this class action lawsuit by June 23, 2026, to pursue claims under federal securities laws and protect their rights.
See More
Class Action Lawsuits Filed for Multiple Companies
- LKQ Corporation Lawsuit: A class action lawsuit for LKQ Corporation alleges that from February 27, 2023, to July 23, 2025, the company failed to disclose risks associated with losing major customers from FinishMaster, negatively impacting its operational and financial performance, with a lead plaintiff deadline of June 22, 2026.
- Regencell Bioscience Lawsuit: The class action for Regencell Bioscience Holdings Limited, covering October 28, 2024, to October 31, 2025, claims the company did not disclose vulnerabilities to market manipulation, exposing shareholders to significant financial risks, with a lead plaintiff deadline of June 23, 2026.
- Globant S.A. Lawsuit: A class action lawsuit against Globant alleges that from February 15, 2024, to August 14, 2025, the company failed to disclose decreasing demand in Latin America and wage freezes, leading to project cancellations, with a lead plaintiff deadline of June 23, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors suffering losses during these periods to contact them for legal rights information, providing phone and email contact details for inquiries.
See More
Regencell Bioscience Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, or risk losing their right to compensation.
- Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation risks and significant financial losses, highlighting the company's vulnerability to regulatory scrutiny.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, indicating its strong track record, which investors should consider when selecting legal counsel.
- Investor Rights Protection: Investors can obtain more information through Rosen Law Firm's website or by phone, and participation in the class action incurs no upfront costs, ensuring their rights to potential recoveries are protected.
See More
